{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:43:10Z","timestamp":1790775790682,"version":"4.1.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T00:00:00Z","timestamp":1620691200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T00:00:00Z","timestamp":1620691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-18-CE18-0023"],"award-info":[{"award-number":["ANR-18-CE18-0023"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Allergic asthma is characterized by elevated levels of IgE antibodies, type 2 cytokines such as interleukin-4 (IL-4) and IL-13, airway hyperresponsiveness (AHR), mucus hypersecretion and eosinophilia. Approved therapeutic monoclonal antibodies targeting IgE or IL-4\/IL-13 reduce asthma symptoms but require costly lifelong administrations. Here, we develop conjugate vaccines against mouse IL-4 and IL-13, and demonstrate their prophylactic and therapeutic efficacy in reducing IgE levels, AHR, eosinophilia and mucus production in mouse models of asthma analyzed up to 15 weeks after initial vaccination. More importantly, we also test similar vaccines specific for human IL-4\/IL-13 in mice expressing human IL-4\/IL-13 and the related receptor, IL-4R\u03b1, to find efficient neutralization of both cytokines and reduced IgE levels for at least 11 weeks post-vaccination. Our results imply that dual IL-4\/IL-13 vaccination may represent a cost-effective, long-term therapeutic strategy for the treatment of allergic asthma as demonstrated\u00a0in mouse models, although additional studies are warranted to assess its safety and feasibility.<\/jats:p>","DOI":"10.1038\/s41467-021-22834-5","type":"journal-article","created":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T16:13:37Z","timestamp":1620749617000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":117,"title":["Dual vaccination against IL-4 and IL-13 protects against chronic allergic asthma in mice"],"prefix":"10.1038","volume":"12","author":[{"given":"Eva","family":"Conde","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Bertrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Balbino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Bonnefoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Stackowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"No\u00e9mie","family":"Caillot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabien","family":"Colaone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"Hamdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ra\u00efssa","family":"Houmadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexia","family":"Loste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8494-613X","authenticated-orcid":false,"given":"Jasper B. J.","family":"Kamphuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8704-1881","authenticated-orcid":false,"given":"Fran\u00e7ois","family":"Huetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Guilleminault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Gaudenzio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Mougel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hardy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John N.","family":"Snouwaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beverly H.","family":"Koller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Serra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Bruhns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9raldine","family":"Grouard-Vogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3384-6769","authenticated-orcid":false,"given":"Laurent L.","family":"Reber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,11]]},"reference":[{"key":"22834_CR1","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nri3786","volume":"15","author":"JV Fahy","year":"2015","unstructured":"Fahy, J. V. Type 2 inflammation in asthma-present in most, absent in many. Nat. Rev. Immunol. 15, 57\u201365 (2015).","journal-title":"Nat. Rev. Immunol."},{"key":"22834_CR2","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1016\/j.rmed.2006.03.031","volume":"100","author":"SP Peters","year":"2006","unstructured":"Peters, S. P., Ferguson, G., Deniz, Y. & Reisner, C. Uncontrolled asthma: a review of the prevalence, disease burden and options for treatment. Respir. Med. 100, 1139\u20131151 (2006).","journal-title":"Respir. Med."},{"key":"22834_CR3","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1056\/NEJMra1608969","volume":"377","author":"E Israel","year":"2017","unstructured":"Israel, E. & Reddel, H. K. Severe and difficult-to-treat asthma in adults. N. Engl. J. Med. 377, 965\u2013976 (2017).","journal-title":"N. Engl. J. Med."},{"key":"22834_CR4","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/nm.2678","volume":"18","author":"SE Wenzel","year":"2012","unstructured":"Wenzel, S. E. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat. Med. 18, 716\u2013725 (2012).","journal-title":"Nat. Med."},{"key":"22834_CR5","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/s41577-018-0006-6","volume":"18","author":"PJ Barnes","year":"2018","unstructured":"Barnes, P. J. Targeting cytokines to treat asthma and chronic obstructive pulmonary disease. Nat. Rev. Immunol. 18, 454\u2013466 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"22834_CR6","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.cyto.2015.05.014","volume":"75","author":"N Gour","year":"2015","unstructured":"Gour, N. & Wills-Karp, M. IL-4 and IL-13 signaling in allergic airway disease. Cytokine 75, 68\u201378 (2015).","journal-title":"Cytokine"},{"key":"22834_CR7","doi-asserted-by":"crossref","unstructured":"Bitton, A. et al. A key role for IL-13 signaling via the type 2 IL-4 receptor in experimental atopic dermatitis. Sci. Immunol. 5, eaaw2938 (2020).","DOI":"10.1126\/sciimmunol.aaw2938"},{"key":"22834_CR8","doi-asserted-by":"crossref","unstructured":"Harb, H. & Chatila, T. A. Mechanisms of dupilumab. Clin. Exp. Allergy 50, 5\u201314 (2019).","DOI":"10.1111\/cea.13491"},{"key":"22834_CR9","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","volume":"378","author":"M Castro","year":"2018","unstructured":"Castro, M. et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N. Engl. J. Med. 378, 2486\u20132496 (2018).","journal-title":"N. Engl. J. Med."},{"key":"22834_CR10","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S1359-6101(03)00004-2","volume":"14","author":"D Zagury","year":"2003","unstructured":"Zagury, D. et al. Active versus passive anti-cytokine antibody therapy against cytokine-associated chronic diseases. Cytokine Growth Factor Rev. 14, 123\u2013137 (2003).","journal-title":"Cytokine Growth Factor Rev."},{"key":"22834_CR11","doi-asserted-by":"publisher","first-page":"7206","DOI":"10.1016\/j.vaccine.2007.07.029","volume":"25","author":"H Le Buanec","year":"2007","unstructured":"Le Buanec, H. et al. Control of allergic reactions in mice by an active anti-murine IL-4 immunization. Vaccine 25, 7206\u20137216 (2007).","journal-title":"Vaccine"},{"key":"22834_CR12","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1165\/rcmb.2012-0060OC","volume":"48","author":"Y Ma","year":"2013","unstructured":"Ma, Y. et al. Sustained suppression of IL-13 by a vaccine attenuates airway inflammation and remodeling in mice. Am. J. Respir. Cell Mol. Biol. 48, 540\u2013549 (2013).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"22834_CR13","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1159\/000447692","volume":"170","author":"D Bagnasco","year":"2016","unstructured":"Bagnasco, D., Ferrando, M., Varricchi, G., Passalacqua, G. & Canonica, G. W. A critical evaluation of anti-IL-13 and anti-IL-4 strategies in severe asthma. Int. Arch. Allergy Immunol. 170, 122\u2013131 (2016).","journal-title":"Int. Arch. Allergy Immunol."},{"key":"22834_CR14","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S2213-2600(16)30265-X","volume":"4","author":"NA Hanania","year":"2016","unstructured":"Hanania, N. A. et al. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir. Med. 4, 781\u2013796 (2016).","journal-title":"Lancet Respir. Med."},{"key":"22834_CR15","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.immuni.2019.03.018","volume":"50","author":"BN Lambrecht","year":"2019","unstructured":"Lambrecht, B. N., Hammad, H. & Fahy, J. V. The cytokines of asthma. Immunity 50, 975\u2013991 (2019).","journal-title":"Immunity"},{"key":"22834_CR16","doi-asserted-by":"publisher","first-page":"5229","DOI":"10.1073\/pnas.1201964109","volume":"109","author":"E Malito","year":"2012","unstructured":"Malito, E. et al. Structural basis for lack of toxicity of the diphtheria toxin mutant CRM197. Proc. Natl Acad. Sci. USA 109, 5229\u20135234 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"22834_CR17","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1016\/j.vaccine.2012.07.074","volume":"31","author":"R Ventura","year":"2013","unstructured":"Ventura, R. et al. Technology transfer of an oil-in-water vaccine-adjuvant for strengthening pandemic influenza preparedness in Indonesia. Vaccine 31, 1641\u20131645 (2013).","journal-title":"Vaccine"},{"key":"22834_CR18","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jaci.2014.10.012","volume":"136","author":"MA Calderon","year":"2015","unstructured":"Calderon, M. A. et al. Respiratory allergy caused by house dust mites: what do we really know? J. Allergy Clin. Immunol. 136, 38\u201348 (2015).","journal-title":"J. Allergy Clin. Immunol."},{"key":"22834_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13696","volume":"7","author":"R Sibilano","year":"2016","unstructured":"Sibilano, R. et al. A TNFRSF14-FcvarepsilonRI-mast cell pathway contributes to development of multiple features of asthma pathology in mice. Nat. Commun. 7, 13696 (2016).","journal-title":"Nat. Commun."},{"key":"22834_CR20","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/1465-9921-8-63","volume":"8","author":"T Glaab","year":"2007","unstructured":"Glaab, T., Taube, C., Braun, A. & Mitzner, W. Invasive and noninvasive methods for studying pulmonary function in mice. Respir. Res 8, 63 (2007).","journal-title":"Respir. Res"},{"key":"22834_CR21","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1080\/17476348.2019.1568245","volume":"13","author":"DW Cockcroft","year":"2019","unstructured":"Cockcroft, D. W., Davis, B. E. & Blais, C. M. Direct bronchoprovocation test methods: history 1945-2018. Expert Rev. Respir. Med. 13, 279\u2013289 (2019).","journal-title":"Expert Rev. Respir. Med."},{"key":"22834_CR22","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.etp.2006.02.014","volume":"57","author":"M Lomask","year":"2006","unstructured":"Lomask, M. Further exploration of the Penh parameter. Exp. Toxicol. Pathol. 57, 13\u201320 (2006). Suppl 2.","journal-title":"Exp. Toxicol. Pathol."},{"key":"22834_CR23","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1172\/JCI85664","volume":"126","author":"C Mesnil","year":"2016","unstructured":"Mesnil, C. et al. Lung-resident eosinophils represent a distinct regulatory eosinophil subset. J. Clin. Investig. 126, 3279\u20133295 (2016).","journal-title":"J. Clin. Investig."},{"key":"22834_CR24","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/nm.2755","volume":"18","author":"SJ Galli","year":"2012","unstructured":"Galli, S. J. & Tsai, M. IgE and mast cells in allergic disease. Nat. Med. 18, 693\u2013704 (2012).","journal-title":"Nat. Med."},{"key":"22834_CR25","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1067\/mai.2001.117880","volume":"108","author":"W Busse","year":"2001","unstructured":"Busse, W. et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J. Allergy Clin. Immunol. 108, 184\u2013190 (2001).","journal-title":"J. Allergy Clin. Immunol."},{"key":"22834_CR26","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1165\/ajrcmb.13.1.7598937","volume":"13","author":"AJ Coyle","year":"1995","unstructured":"Coyle, A. J. et al. Interleukin-4 is required for the induction of lung Th2 mucosal immunity. Am. J. Respir. Cell Mol. Biol. 13, 54\u201359 (1995).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"22834_CR27","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1165\/ajrcmb.12.3.7873190","volume":"12","author":"G Brusselle","year":"1995","unstructured":"Brusselle, G., Kips, J., Joos, G., Bluethmann, H. & Pauwels, R. Allergen-induced airway inflammation and bronchial responsiveness in wild-type and interleukin-4-deficient mice. Am. J. Respir. Cell Mol. Biol. 12, 254\u2013259 (1995).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"22834_CR28","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1126\/science.282.5397.2261","volume":"282","author":"G Grunig","year":"1998","unstructured":"Grunig, G. et al. Requirement for IL-13 independently of IL-4 in experimental asthma. Science 282, 2261\u20132263 (1998).","journal-title":"Science"},{"key":"22834_CR29","doi-asserted-by":"crossref","unstructured":"Wills-Karp, M. & Finkelman, F. D. Untangling the complex web of IL-4- and IL-13-mediated signaling pathways. Sci. Signal. 1, pe55 (2008).","DOI":"10.1126\/scisignal.1.51.pe55"},{"key":"22834_CR30","doi-asserted-by":"publisher","first-page":"888","DOI":"10.3389\/fimmu.2018.00888","volume":"9","author":"IS Junttila","year":"2018","unstructured":"Junttila, I. S. Tuning the cytokine responses: an update on interleukin (IL)-4 and IL-13 receptor complexes. Front. Immunol. 9, 888 (2018).","journal-title":"Front. Immunol."},{"key":"22834_CR31","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nm1332","volume":"12","author":"S Fichtner-Feigl","year":"2006","unstructured":"Fichtner-Feigl, S., Strober, W., Kawakami, K., Puri, R. K. & Kitani, A. IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat. Med. 12, 99\u2013106 (2006).","journal-title":"Nat. Med."},{"key":"22834_CR32","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/S2213-2600(15)00197-6","volume":"3","author":"CE Brightling","year":"2015","unstructured":"Brightling, C. E. et al. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Respir. Med. 3, 692\u2013701 (2015).","journal-title":"Lancet Respir. Med."},{"key":"22834_CR33","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1183\/09031936.00223411","volume":"41","author":"E Piper","year":"2013","unstructured":"Piper, E. et al. A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma. Eur. Respir. J. 41, 330\u2013338 (2013).","journal-title":"Eur. Respir. J."},{"key":"22834_CR34","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.jaci.2006.02.046","volume":"118","author":"G Takayama","year":"2006","unstructured":"Takayama, G. et al. Periostin: a novel component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13 signals. J. Allergy Clin. Immunol. 118, 98\u2013104 (2006).","journal-title":"J. Allergy Clin. Immunol."},{"key":"22834_CR35","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/S2213-2600(18)30184-X","volume":"6","author":"RA Panettieri Jr.","year":"2018","unstructured":"Panettieri, R. A. Jr. et al. Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials. Lancet Respir. Med. 6, 511\u2013525 (2018).","journal-title":"Lancet Respir. Med."},{"key":"22834_CR36","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1164\/rccm.201712-2382OC","volume":"198","author":"D Lightwood","year":"2018","unstructured":"Lightwood, D. et al. Efficacy of an inhaled IL-13 antibody fragment in a model of chronic asthma. Am. J. Respir. Crit. Care Med. 198, 610\u2013619 (2018).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"22834_CR37","doi-asserted-by":"publisher","first-page":"7716","DOI":"10.4049\/jimmunol.174.12.7716","volume":"174","author":"SC Fish","year":"2005","unstructured":"Fish, S. C., Donaldson, D. D., Goldman, S. J., Williams, C. M. & Kasaian, M. T. IgE generation and mast cell effector function in mice deficient in IL-4 and IL-13. J. Immunol. 174, 7716\u20137724 (2005).","journal-title":"J. Immunol."},{"key":"22834_CR38","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1111\/all.14151","volume":"75","author":"A Le Floc\u2019h","year":"2020","unstructured":"Le Floc\u2019h, A. et al. Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Ralpha antibody, is required to broadly inhibit type 2 inflammation. Allergy 75, 1188\u20131204 (2020).","journal-title":"Allergy"},{"key":"22834_CR39","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1038\/jid.2014.198","volume":"134","author":"NR Han","year":"2014","unstructured":"Han, N. R. et al. TSLP induces mast cell development and aggravates allergic reactions through the activation of MDM2 and STAT6. J. Investig. Dermatol. 134, 2521\u20132530 (2014).","journal-title":"J. Investig. Dermatol."},{"key":"22834_CR40","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1126\/science.1240342","volume":"341","author":"VO Millien","year":"2013","unstructured":"Millien, V. O. et al. Cleavage of fibrinogen by proteinases elicits allergic responses through Toll-like receptor 4. Science 341, 792\u2013796 (2013).","journal-title":"Science"},{"key":"22834_CR41","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1136\/annrheumdis-2019-216379","volume":"79","author":"FA Houssiau","year":"2020","unstructured":"Houssiau, F. A. et al. IFN-alpha kinoid in systemic lupus erythematosus: results from a phase IIb, randomised, placebo-controlled study. Ann. Rheum. Dis. 79, 347\u2013355 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"22834_CR42","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1093\/rheumatology\/kew262","volume":"55","author":"J Ducreux","year":"2016","unstructured":"Ducreux, J. et al. Interferon alpha kinoid induces neutralizing anti-interferon alpha antibodies that decrease the expression of interferon-induced and B cell activation associated transcripts: analysis of extended follow-up data from the interferon alpha kinoid phase I\/II study. Rheumatology 55, 1901\u20131905 (2016).","journal-title":"Rheumatology"},{"key":"22834_CR43","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1146\/annurev-immunol-032712-095906","volume":"31","author":"SJ Van Dyken","year":"2013","unstructured":"Van Dyken, S. J. & Locksley, R. M. Interleukin-4- and interleukin-13-mediated alternatively activated macrophages: roles in homeostasis and disease. Annu. Rev. Immunol. 31, 317\u2013343 (2013).","journal-title":"Annu. Rev. Immunol."},{"key":"22834_CR44","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/j.1365-3024.2006.00920.x","volume":"29","author":"HE Scales","year":"2007","unstructured":"Scales, H. E., Ierna, M. X. & Lawrence, C. E. The role of IL-4, IL-13 and IL-4Ralpha in the development of protective and pathological responses to Trichinella spiralis. Parasite Immunol. 29, 81\u201391 (2007).","journal-title":"Parasite Immunol."},{"key":"22834_CR45","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/j.0105-2896.2004.00192.x","volume":"201","author":"FD Finkelman","year":"2004","unstructured":"Finkelman, F. D. et al. Interleukin-4- and interleukin-13-mediated host protection against intestinal nematode parasites. Immunol. Rev. 201, 139\u2013155 (2004).","journal-title":"Immunol. Rev."},{"key":"22834_CR46","doi-asserted-by":"crossref","unstructured":"Nettis, E. et al. Long-term effectiveness of dupilumab up to 52 weeks in atopic dermatitis in 253 adult patients. Br. J. Dermatol. 184, 561\u2013563 (2021).","DOI":"10.1111\/bjd.19577"},{"key":"22834_CR47","doi-asserted-by":"publisher","first-page":"701","DOI":"10.2147\/JAA.S275068","volume":"13","author":"ID Pavord","year":"2020","unstructured":"Pavord, I. D. et al. Dupilumab efficacy in patients stratified by baseline treatment intensity and lung function. J. Asthma Allergy 13, 701\u2013711 (2020).","journal-title":"J. Asthma Allergy"},{"key":"22834_CR48","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jaad.2020.08.051","volume":"84","author":"AS Halling","year":"2021","unstructured":"Halling, A. S., Loft, N., Silverberg, J. I., Guttman-Yassky, E. & Thyssen, J. P. Real-world evidence of dupilumab efficacy and risk of adverse events: a systematic review and meta-analysis. J. Am. Acad. Dermatol. 84, 139\u2013147 (2021).","journal-title":"J. Am. Acad. Dermatol."},{"key":"22834_CR49","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jaad.2019.07.074","volume":"82","author":"M Deleuran","year":"2020","unstructured":"Deleuran, M. et al. Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study. J. Am. Acad. Dermatol. 82, 377\u2013388 (2020).","journal-title":"J. Am. Acad. Dermatol."},{"key":"22834_CR50","doi-asserted-by":"crossref","unstructured":"Wechsler M. E. et al. Late breaking abstract - dupilumab long-term safety and efficacy in patients with asthma: LIBERTY ASTHMA TRAVERSE. Eur. Respir. J. 56, 4613 (2020).","DOI":"10.1183\/13993003.congress-2020.4613"},{"key":"22834_CR51","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/bjd.17869","volume":"181","author":"B Akinlade","year":"2019","unstructured":"Akinlade, B. et al. Conjunctivitis in dupilumab clinical trials. Br. J. Dermatol 181, 459\u2013473 (2019).","journal-title":"Br. J. Dermatol"},{"key":"22834_CR52","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1016\/j.celrep.2016.11.052","volume":"17","author":"JN Snouwaert","year":"2016","unstructured":"Snouwaert, J. N. et al. An NLRP3 mutation causes arthropathy and osteoporosis in humanized mice. Cell Rep. 17, 3077\u20133088 (2016).","journal-title":"Cell Rep."},{"key":"22834_CR53","doi-asserted-by":"publisher","first-page":"e91206","DOI":"10.1371\/journal.pone.0091206","volume":"9","author":"S Post","year":"2014","unstructured":"Post, S. et al. Protease-activated receptor-2 activation contributes to house dust mite-induced IgE responses in mice. PLoS One 9, e91206 (2014).","journal-title":"PLoS One"},{"key":"22834_CR54","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.ajpath.2012.06.031","volume":"181","author":"PS Milutinovic","year":"2012","unstructured":"Milutinovic, P. S., Alcorn, J. F., Englert, J. M., Crum, L. T. & Oury, T. D. The receptor for advanced glycation end products is a central mediator of asthma pathogenesis. Am. J. Pathol. 181, 1215\u20131225 (2012).","journal-title":"Am. J. Pathol."},{"key":"22834_CR55","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1084\/jem.20030298","volume":"198","author":"S Myou","year":"2003","unstructured":"Myou, S. et al. Blockade of inflammation and airway hyperresponsiveness in immune-sensitized mice by dominant-negative phosphoinositide 3-kinase-TAT. J. Exp. Med. 198, 1573\u20131582 (2003).","journal-title":"J. Exp. Med."},{"key":"22834_CR56","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1007\/PL00000243","volume":"50","author":"H Tanaka","year":"2001","unstructured":"Tanaka, H. et al. The effect of allergen-induced airway inflammation on airway remodeling in a murine model of allergic asthma. Inflamm. Res. 50, 616\u2013624 (2001).","journal-title":"Inflamm. Res."},{"key":"22834_CR57","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1016\/j.jaci.2013.01.029","volume":"131","author":"N Gaudenzio","year":"2013","unstructured":"Gaudenzio, N., Laurent, C., Valitutti, S. & Espinosa, E. Human mast cells drive memory CD4+ T cells toward an inflammatory IL-22+ phenotype. J. Allergy Clin. Immunol. 131, 1400\u20131407 e1411 (2013).","journal-title":"J. Allergy Clin. Immunol."},{"key":"22834_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7174","volume":"6","author":"R Joulia","year":"2015","unstructured":"Joulia, R. et al. Mast cells form antibody-dependent degranulatory synapse for dedicated secretion and defence. Nat. Commun. 6, 6174 (2015).","journal-title":"Nat. Commun."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-22834-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-22834-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-22834-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T12:05:10Z","timestamp":1669982710000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-22834-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,11]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["22834"],"URL":"https:\/\/doi.org\/10.1038\/s41467-021-22834-5","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,11]]},"assertion":[{"value":"26 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"E.C., R.B., P.B., N.C., V.S., G.G.-V., and L.L.R. are inventors on patent related to this work (WO2019228674 (A1)), and\/or related to Kinoid technology. E.C., R.B., J.B., N.C., F.C., S.H., V.S., and G.G.-V. are currently or were previously employees of NEOVACS and company stocks owners. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2574"}}